Iproteos closes the first ‘crowdfunding’ campaign of the Spanish biotech sector Blog Post

The biotech Iproteos -located at the Parc Cientific de Barcelona- has managed to successfully close an innovative funding campaign based on equity crowdfunding with the aim of raising € 100,000 for the development of a new drug to stop progression and reverse the cognitive deficits associated with schizophrenia: IPR019. The funds raised will allow the biotech -a spin-off from the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) – complete the preclinical non-regulatory stage of the compound to begin clinical trials in 2016.